Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 18 symbols : NVS save search
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
Published: 2021-03-18 (Crawled : 22:00) - biospace.com/
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -1.05%
H: 0.86%
C: -1.4%
covid treatment results respiratory phase 3 syndros
Global Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Analysis
Published: 2021-03-18 (Crawled : 17:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.73%
H: 1.24%
C: 0.68%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
covid system covid-19
Global Dermatology Drugs Market Report 2020: Market is Expected to Advance Rapidly to 2023 - Long-term Forecast to 2030
Published: 2021-03-18 (Crawled : 15:30) - prnewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.93%
C: -1.85%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.99%
H: 0.95%
C: -0.22%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -1.54%
H: 2.76%
C: 1.63%
drug
Novartis' KISQALI (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
Published: 2021-03-18 (Crawled : 12:30) - biospace.com/
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
women cancer breast cancer her2+ her2- her2
Global Alcoholic Hepatitis Treatment Market to grow by USD 695.42 Million during 2021-2025|5.98% Year-Over-Year Growth in 2021|Technavio
Published: 2021-03-18 (Crawled : 01:00) - prnewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
treatment hepatitis growth
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.